

BioChem Solutions Inc. names CEO, three new directors

BioChem Solutions Inc. names CEO, three new directors

Frankfurt, Germany -- BioChem Solutions Inc. today named James C. Shelley, former president of the Bank of America (Canada), as president and chief executive officer, effective immediately.

Three new directors also were named as part of BioChem's transition into full-scale pharmaceutical production and global sales from a predominantly research-and-testing orientation.

Shelley, 65, has held various senior management positions in the banking industry across North America, including Citibank and Union Planters National Bank. Most recently he was president of Curragh West Management Ltd., private bankers and trust originators headquartered in Nassau, The Bahamas. A resident of Toronto, Canada, Shelley is a magna cum laude graduate of the College of the City of New York.

Tony Georges Licha'a, M.D., a pioneer in chelation therapy with a worldwide anti-aging medical practice headquartered in Beirut, Lebanon, was named chairman of the board. Licha'a, 53, succeeds W. Jean Herman, who resigned to spend more time with her family. As chairman, Licha'a has leadership responsibility for the company's overall governance and corporate policies.

Jason Taite, with management experience at several major Canadian firms, was named a director. Taite succeeds John Alexander Corrie, who resigned for personal reasons. Taite, 35, a resident of Quebec, Canada, will assume particular responsibility for oversight of BioChem's day-to-day operations.

Eston E. Melton III has been named an additional director. Melton, 54, previously an award-winning print journalist and for 26 years a corporate consultant in Miami, Florida, will assume particular responsibility for oversight of BioChem's logistic planning and implementation.

Continuing on the board are Directors James A. Herman and Davy K. Koech, Ph.D. Herman, 51, has particular responsibility for oversight of BioChem's continuing research and development initiatives; he resides in Hudson, Ohio. Koech, 54, has particular responsibility for oversight of BioChem's medical testing and protocol compliance; he resides in Nairobi, Kenya.

"Jim Shelley brings a tremendous breadth of marketplace experience to BioChem Solutions, and in precisely those areas that our corporate development requires at this moment," said board chairman Licha'a, in making the announcement. "We are both fortunate and thrilled to have such talent join our organization."

Garth Jensen, 55, continues as chief financial officer.

BioChem Solutions holds the worldwide master license to produce and distribute all products that incorporate the patented product Trioxolane as an active ingredient. Its first products are the trademarked derivatives Arthromir and Alphamir. Preliminary studies strongly suggest that Arthromir has significant potential in the clinical management of rheumatoid arthritis, while Alphamir shows similar promise in the treatment of HIV/AIDS patients.

BioChem Solutions also holds the global master license to produce and market medications derived

from the patented product Diperoxide. In trials to date, both Trioxolane and Diperoxide derivatives have shown significant improvement in the function of the human immune system using a variety of indicators.

The use of these derivatives has potential in destroying tumor cells and harmful micro-organisms such as bacteria, viruses, parasites and fungi. Treatment is non-toxic and has shown no adverse side effects. Moreover, these products reinforce natural immune systems in combating harmful agents and regulating the beneficial production of serotonin, prostaglandin and inflammatory interleukins.

Company representatives recently concluded their second multi-city trip to India, exploring opportunities for commercial development of its patented products and potential business alliances.

Company Contact:

www.biochemsolutiosinc.com -- info@biochemsolutionsinc.com

Company Address:

80 SW 8th Street, Suite 2000, Miami, FL 33130, USA

Share Information:

WKN: A0J36E, ISIN: US0909651046

Investor Relations:

Connecting Markets GmbH, E. Akay – akay@cmir.de

FON + 49 (0) 69 – 21 65 59 10 FAX + 49 (0) 69 – 21 65 59 11

Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company's actual results could differ materially from those anticipated in the forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender verantwortlich.

Kostenloser Abdruck mit Quellenangabe erlaubt.

Jljlklk;l

Llaalka;la

Alja;ll;al